Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

50 results about "Histamine h" patented technology

Tetrahydroisoquinoline compounds

Certain tetrahydroisoquinoline compounds are histamine H3 receptor and serotonin transporter modulators useful in the treatment of histamine H3 receptor- and serotonin-mediated diseases.
Owner:JANSSEN PHARMA NV

Non-Imidazole heterocyclic compounds

Certain non-imidazole heterocyclic compounds are histamine H3 modulators useful in the treatment of histamine H3 receptor mediated diseases.
Owner:JANSSEN PHARMA NV

Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor

ActiveUS20090156613A1BiocideOrganic chemistryHistamine H1 receptorDisease
Bicyclic heteroaryl-substituted imidazole compounds are described, which are useful as H4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the modulation of histamine H4 receptor activity and for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.
Owner:JANSSEN PHARMA NV

Pyridine compounds as histamine H3 modulators

ActiveUS7423147B2BiocideNervous disorderHistamine H1 receptorHistamine H2 receptor
Certain non-imidazole heterocyclic compounds are Histamine H3 modulators in the treatment of Histamine H3 receptor mediated diseases.
Owner:JANSSEN PHARMA NV

Thieno-and furo-pyrimidine modulators of the histamine H4 receptor

Thieno- and furo-pyrimidine compounds are described, which are useful as H4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the modulation of histamine H4 receptor activity and for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as inflammation.
Owner:JANSSEN PHARMA NV

2-aminopyrimidine modulators of the histamine H4 receptor

InactiveUS7923451B2BiocideOrganic active ingredientsHistamine H1 receptorDisease
2-Aminopyrimidine compounds are described, which are useful as H4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.
Owner:JANSSEN PHARMA NV

Method for treatment of neurodegenerative diseases and effects of aging

InactiveUS7232830B2Increase neuronalIncrease neuronal metabolismBiocideNervous disorderAutoimmune diseaseMethyltransferase
A method for treatment of neurodegenerative disease conditions stemming from multiple sclerosis, aging, autoimmune diseases and fibromyalgia. A compound effective to increase neuronal metabolism of histamine to a histamine H2 agonist is administered in an amount sufficient to stimulate production of cyclic AMP at a level which is sufficient to maintain myelin against undergoing self-degeneration. The compound is selected from the group consisting of histamine M-methyltransferase, monoamineoxidase-A, monoamineoxidase-A agonists and histamine H3 antagonists. The histamine M-methyltransferase may be administered to increase neuronal metabolism of histamine to tele-methylhistamine, whereas the monoamineoxidase-A or monoamineoxidase-A agonist may be administered so as to increase neuronal metabolism of telemethylhistamine to an H2 agonist. Separately or in conjunction with the others, the histamine H3 antagonist may be administered so as to inhibit metabolism of the telemethylhistamine to an H3 agonist, thereby increasing metabolism of the telemethylhistamine to an H2 agonist. The increased histamine H2 agonist levels reduce demyelination and the symptoms that are associated with these conditions.
Owner:EAD

Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor

ActiveUS8084466B2BiocideOrganic chemistryHistamine H1 receptorDisease
Bicyclic heteroaryl-substituted imidazole compounds are described, which are useful as H4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the modulation of histamine H4 receptor activity and for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.
Owner:JANSSEN PHARMA NV

Furan compounds as histamine H3 modulators

ActiveUS7429659B2Organic active ingredientsNervous disorderFuranHistamine H1 receptor
Certain furan compounds are histamine H3 modulators useful in the treatment of histamine H3 receptor mediated diseases.
Owner:JANSSEN PHARMA NV

Non-imidazole heterocyclic compounds

Certain non-imidazole heterocyclic compounds are histamine H3 modulators useful in the treatment of histamine H3 receptor mediated diseases.
Owner:JANSSEN PHARMA NV

Thieno- and furo-pyrimidine modulators of the histamine H4 receptor

Thieno- and furo-pyrimidine compounds are described, which are useful as H4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the modulation of histamine H4 receptor activity and for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as inflammation.
Owner:JANSSEN PHARMA NV

Liquid pharmaceutical composition

This invention relates to new pharmaceutical compositions and methods for their preparation, and in particular it relates to taste-masked liquid compositions comprising a solution of a histamine H2-antagonist complexed with an alginate and also containing a humectant. The solution is buffered to a pH of between about 6 to 7. The inventive solution may be flavored and sweetened and preserved.
Owner:BRAINTREE LAB

Pyrazoles for the treatment of obesity and other CNS disorders

This invention relates to compounds having pharmacological activity, to compositions containing these compounds, and to a method of treatment employing the compounds and compositions. More particularly, this invention concerns certain pyrazole derivatives, their salts and solvates. These compounds have H3 histamine receptor binding activity. This invention also relates to pharmaceutical compositions containing these compounds and to a method of treating disorders in which histamine H3 receptor modulation is beneficial.
Owner:ATHERSYS

Combination of an h2-receptor antagonist, antacid, and alginic acid to treat episodic heartburn

A combination of an antacid, alginate, and a histamine H2-receptor antagonist, and methods of using the same for providing fast and lasting relief of symptoms of episodic heartburn are provided.
Owner:WOLFE M MICHAEL

Deuterated pharmaceutical compositions and methods of treating cardiovascular diseases

Provided herein is a pharmaceutical composition comprising (i) a phosphodiesterase inhibitor or an adenosine receptor antagonist, (ii) a calcium channel blocker, (iii) a histamine H1-receptor agonist, a histamine H2-receptor agonist, or a histamine H3-receptor antagonist, and (iv) a β2-adrenoreceptor agonist; wherein at least one of two or more active pharmaceutical compounds is deuterium enriched. Also provided herein is a pharmaceutical composition comprising at least one of two or more deuterated compounds which increase pharmacokinetic half-life (increasing the duration of action) and reduce side effects by allowing for reduction of the dose levels. A method of use thereof pharmaceutical composition for treating, preventing, or ameliorating a cardiovascular disease.
Owner:CARDIX THERAPEUTICS LLC

Analyzing Histamine H4 Receptor-Mediated Effects In Whole Blood

Assay methods for analyzing whole blood to detect histamine H4 receptor-mediated effects, such as eosinophil shape change, cytoskeletal change, adhesion molecule up-regulation, or calcium flux are described. Such methods are useful in clinical and diagnostic applications.
Owner:KARLSSON LARS +3

Compositions and methods for treating or preventing gastrointestinal disorders and gerd-related respiratory disorders

Disclosed herein are novel compositions and methods for treating or preventing GI tract disorders and / or GERD-related respiratory disorders as well as protecting stratified squamous epithelium against injury by a noxious substance. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising at least one bile acid sequestrant, alone or in combination with at least one proton pump inhibitor, and optionally one or more agent chosen from antacids, histamine H2-receptor antagonists, γ-aminobutyricacid-b (GABA-B) agonists, prodrugs of GABA-B agonists, and protease inhibitors.
Owner:IRONWOOD PHARMA

Method and compositions for reducing cardiac dysfunctions with a selective histamine H3 receptor agonist

The invention provides a method for reducing cardiac dysfunctions in a human. The method comprises administration to the human of an effective amount of a selective histamine H3 Receptor agonist. In one embodiment, the method comprises limiting the accumulation of intracellular sodium (Nai) by inhibiting the Na+ / H+ exchanger activity in the human having a cardiac dysfunction, or a predisposition to a cardiac dysfunction. In another embodiment the method comprises inhibiting the N-type Ca2+ channel to modulate the concentration of intracellular calcium. The invention also provides a pharmaceutical composition that includes a selective histamine H3 Receptor agonist with a pharmaceutical carrier.
Owner:CORNELL RES FOUNDATION INC

Pharmaceutical compositions and methods of treating cardiovascular diseases

Provided herein is a pharmaceutical composition comprising two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a β2-adrenoreceptor agonist. Also provided herein is a method of treating, preventing, or ameliorating a cardiovascular disease in a subject, comprising administering to the subject in need thereof two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a β2-adrenoreceptor agonist.
Owner:CARDIX THERAPEUTICS LLC

Treatment Of Stroke With Histamine H3 Inverse Agonists Or Histamine H3 Antagonists

InactiveUS20080139614A1BiocideNervous disorderHistamine antagonistsRisk stroke
Histamine H3 inverse agonists or histamine H3 antagonists are useful, alone or in combination with an anti-stroke agent, for treating stroke.
Owner:MERCK & CO INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products